Hutch News

Hutch News

Stories tagged 'T cell'

Good News at Fred Hutch

Celebrating faculty and staff achievements

Nov. 21, 2016

Good News: Ceballos honored for public health research; ACS research awards to three Hutch scientists; ASH grant to physician-researcher Halpern; Paulovich facilitates Moonshot panel

View story >


Fred Hutch opens first-of-its kind Bezos Family Immunotherapy Clinic

Clinic will allow researchers to conduct twice as many immunotherapy trials, enable intensive patient monitoring to improve experimental therapies

Nov. 1, 2016 | By Fred Hutch News Service

The new clinic will allow researchers to conduct twice as many immunotherapy trials and enable intensive patient monitoring to improve experimental therapies.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Sept. 16, 2016

Hyundai Hope on Wheels gives $250K grant for pediatric cancer research; Drs. Amanda Paulovich and Jeff Whiteaker facilitate "first step" in expanding NCI’s Protein Assay Portal.

View story >


Patients with advanced lymphoma in remission after T-cell therapy

New study: 7 of 11 trial participants who got two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission

Sept. 7, 2016 | By Susan Keown / Fred Hutch News Service

Seven of 11 trial participants who got a two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission, a new study found.

View story >


Investing in the future

Five researchers get surprise grants through new President’s Young Investigator Awards

June 27, 2016 | By Sabin Russell / Fred Hutch News Service

This spring, five “young investigators” working at the Seattle cancer research center ― or soon to join it ― received entirely unexpected notes from Fred Hutch president and director Dr. Gary Gilliland. And the notes carried a bigger surprise. Each scientist had been awarded a $100,000 grant for “unrestricted” research in their laboratories.

View story >


Dramatic remissions seen in immunotherapy trial of blood cancer patients

Experimental, living T-cell therapy shows promise for treating advanced disease, making immunotherapy a ‘pillar’ of cancer care

Feb. 16, 2016 | By Andrea Detter / Fred Hutch News Service

Many patients with advanced blood cancers who are receiving experimental, “living” immunotherapy as part of a clinical trial are experiencing sustained remissions, according to preliminary results of the ongoing study at Fred Hutchinson Cancer Research Center.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.